Kabra Drugs Board to consider major diversification into Drones, AI, Dairy

Kabra Drugs Ltd. has scheduled a Board Meeting on April 21, 2026, to discuss significant strategic initiatives. The agenda includes the proposed appointment of Ms. Monam Kapoor as an Additional Non-Executive Independent Director. Crucially, the Board will consider amending the Memorandum of Association to facilitate a major business diversification. New proposed segments include manufacturing and distribution of Drones & Defence equipment, Hospital & Medical equipment, and all types of dairy products. The company also aims to enter AI technologies (software & hardware), Hospitality, and agro farming/products. Additionally, the Board will approve a Postal Ballot notice to seek shareholder approval for these proposed changes, fix a cut-off date, and appoint a scrutinizer for the e-voting process. This move signals a strategic shift towards broader market segments beyond its traditional drug business.